BioAtla, Inc. Common Stock
BCABBioAtla, Inc. (BCAB) is a biotechnology company focused on developing next-generation antibody-based therapeutics for cancer and other serious diseases. The company specializes in its proprietary AZCT (A priori, Target, and Location-Validated Antibody-Drug Conjugate) platform, which aims to create targeted treatments with improved safety and efficacy. BioAtla's pipeline includes innovative immuno-oncology and targeted therapy candidates.
Company News
BioAtla and GATC Health announced a $40 million special purpose vehicle transaction to advance ozuriftamab vedotin (Oz-V) into a Phase 3 registrational trial for 2L+ oropharyngeal squamous cell carcinoma. BioAtla will receive an initial $5 million with the remaining $35 million expected in Q1 2026, retaining 65% ownership of Oz-V while Inversagen...
BioAtla secured $7.5 million in pre-paid advance agreements with Yorkville Advisors and Anson Advisors, providing financial flexibility while pursuing a strategic partnership expected to complete by year-end.
BioAtla presented clinical data on its antibody-drug conjugate Ozuriftamab Vedotin (Oz-V) at the International Papillomavirus Society Conference, highlighting its potential in treating HPV-positive oropharyngeal squamous cell carcinoma with promising Phase 2 trial results.
BioAtla will present clinical data for its investigational AXL-targeting antibody-drug conjugate (mecbotamab vedotin) at the SITC 2025 Annual Meeting, highlighting results from a study on treatment-refractory sarcoma patients.
BioAtla, a clinical-stage biotechnology company, will host a conference call on August 7, 2025 to discuss its Q2 financial results and business highlights, focusing on its Conditionally Active Biologic (CAB) antibody therapeutics for solid tumor treatment.
